Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Cisplatin- or Oxaliplatin-Induced Peripheral Neuropathy With Alpha-Lipoic Acid: A Placebo-Controlled Phase III Trial

NCT00112996 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00112996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00112996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Cisplatin- or Oxaliplatin-Induced Peripheral Neuropathy With Alpha-Lipoic Acid: A Placebo-Controlled Phase III Trial
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2007
Completion date
April 30, 2014
Enrollment
244 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

neurotoxicity, unspecified adult solid tumor, protocol specific, unspecified childhood solid tumor, protocol specific